News
Dimerix has received a US$30m (~$48m) upfront payment from Amicus Therapeutics under a US licensing deal for its phase III ..
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback